Evidence map›Paper›PMID 40932248›Full record

ArticleJournal of virology2025

From phenotype to receptor: validating physiological clustering of

Tomoyoshi Kaneko, Toshifumi Osaka, Minoru Inagaki, Kento Habe, Takuma Okabe, Satoshi Tsuneda

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A two-step bioconjugation ofRSC chemical biology · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoyoshi KanekoDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.ORCID 0000-0003-4857-4700
Toshifumi OsakaDepartment of Microbiology and Immunology, Tokyo Women's Medical University, Tokyo, Japan.
Minoru InagakiDepartment of Life Science, Faculty of Bioresources, Mie University, Mie, Japan.
Kento HabeDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
Takuma OkabeDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
Satoshi TsunedaDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.ORCID 0000-0002-4624-5359

Funding

Waseda University 2022C-160
6 · The paper itself

Abstract

Understanding the relationship between bacteriophage (phage) classification and target receptors is crucial for phage ecology and applied research. In this study, we compared 13 previously isolated IMPORTANCE: Phage therapy is gaining attention as an alternative treatment for antibiotic-resistant bacteria. Developing effective phage cocktails requires combining phages with different target receptors, but traditional methods for identifying target receptors are labor-intensive. This study demonstrates that E. coli phages targeting the TK001 strain with different target receptors can be grouped based on their physiological characteristics, tail fiber sequences, or whole genomes. Our approach was enhanced through systematic bacterial panel selection for host range assessment, optimized distance metrics for physiological characteristics, and objective cluster determination using silhouette coefficient analysis for all three classifications. This insight can be used to more efficiently create diverse phage cocktails. Additionally, we identified phages targeting diverse sites, including different regions of LPS, membrane proteins, and flagella. These findings deepen our understanding of phage host recognition mechanisms, enabling the rapid preparation of effective phage cocktails and contributing to new advancements in bacterial infection treatment.

Indexed as

ColiphagesEscherichia coliReceptors, VirusEscherichia coli ProteinsGenome, ViralHost SpecificityLipopolysaccharidesPhenotypePhylogenyEscherichia coli ProteinsLipopolysaccharidesReceptors, VirusbacteriophageEscherichia colilipopolysaccharidephage classificationtarget receptor

Identifiers

PMID40932248
PMCPMC12548472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.